- Home
- KPLT vs IMMX Comparison
KPLT vs IMMX Comparison
Compare KPLT & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPLT | IMMX |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.2M | 82.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KPLT | IMMX |
|---|---|---|
| Price | $7.36 | $7.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $12.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $280,839,000.00 | N/A |
| Revenue This Year | $21.42 | N/A |
| Revenue Next Year | $15.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $5.08 | $1.34 |
| 52 Week High | $24.34 | $7.73 |
Technical Indicators
Market Signals| Indicator | KPLT | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 79.16 |
| Support Level | $6.00 | $4.50 |
| Resistance Level | $7.00 | $4.48 |
| Average True Range (ATR) | 0.58 | 0.62 |
| MACD | 0.31 | 0.28 |
| Stochastic Oscillator | 35.88 | 83.29 |
Price Performance
Historical ComparisonAbout KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.